Search results
Showing 251 to 300 of 2065 results for work
Awaiting development Reference number: GID-TA10605 Expected publication date: TBC
Awaiting development Reference number: GID-TA10657 Expected publication date: TBC
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer (TA1071)
Evidence-based recommendations on atezolizumab (Tecentriq) for the adjuvant treatment of resected non-small-cell lung cancer in adults.
Mirikizumab for previously treated moderately to severely active Crohn's disease (TA1080)
Evidence-based recommendations on mirikizumab (Omvoh) for previously treated moderately to severely active Crohn's disease in adults.
Topic prioritisation
Implanting a baroreceptor stimulation device for resistant hypertension
In development Reference number: GID-IP1180 Expected publication date: TBC
This interim statement outlines early value assessments, a new evidence-based approach designed to improve the care of people and effective use of NHS resources through quicker access to promising health technologies that address national unmet need
This quality standard covers renal replacement therapy services for adults with kidney failure. It includes treatment options, such as dialysis and kidney transplant. It describes high-quality care in priority areas for improvement.
View quality statements for QS72Show all sections
Sections for QS72
- Quality statements
- Quality statement 1: Education programmes
- Quality statement 2: Transplantation – pre-emptive
- Quality statement 3: Transplantation – on dialysis
- Quality statement 4: Dialysis access preparation
- Quality statement 5: Home-based dialysis
- Quality statement 6: Patient transport
- Quality statement 7: Transplantation – rapid access to a specialist histopathology service
Awaiting development Reference number: GID-TA10519 Expected publication date: TBC
Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema (TA953)
Evidence-based recommendations on fluocinolone acetonide intravitreal implant (Iluvien) for visual impairment caused by chronic diabetic macular oedema that has not responded well enough to available treatments in adults.
Help us improve NICE: take part in research to help us develop better products and services.
Read biographies of the members of our quality standards advisory committee.
Upadacitinib for previously treated moderately to severely active Crohn's disease (TA905)
Evidence-based recommendations on upadacitinib (Rinvoq) for previously treated moderately to severely active Crohn’s disease in adults.
This guideline covers good practice for developing and updating local formularies in line with statutory requirements. It supports developing formularies that reflect local needs, reduce variation in prescribing, and allow rapid adoption of new medicines and treatments.
View recommendations for MPG1Show all sections
This guideline covers care and support for adults with cerebral palsy. It aims to improve health and wellbeing, promote access to services and support participation and independent living.
a stakeholder People and communities - putting you at the heart of our work Help develop quality standards Help us improve Help...
Awaiting development Reference number: GID-TA11500 Expected publication date: TBC
Topic prioritisation
Evidence-based recommendations on vanzacaftor-tezacaftor-deutivacaftor (Alyftrek) for treating cystic fibrosis in people 6 years and over with an F508del mutation in the cystic fibrosis transmembrane conductance regulator gene.
Transcatheter tricuspid valve implantation for symptomatic severe tricuspid regurgitation
In development Reference number: GID-IPG10416 Expected publication date: 04 March 2026
Read biographies of the members of our quality standards advisory committee.
Read biographies for all members of NICE's indicator advisory committee.
Evidence-based recommendations on rimegepant (Vydura) for the acute treatment of migraine in adults.
Toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer ID6406
In development Reference number: GID-TA11341 Expected publication date: TBC
This guideline covers general principles for prescribing and managing withdrawal from opioids, benzodiazepines, gabapentinoids, Z-drugs and antidepressants in primary and secondary care.
Guide for lay members who we've invited to sit on one of NICE's committees, panels, or groups.
This guideline covers decision-making in people 16 years and over who may lack capacity now or in the future. It aims to help health and social care practitioners support people to make their own decisions where they have the capacity to do so. It also helps practitioners to keep people who lack capacity at the centre of the decision-making process.
Cabozantinib for previously treated advanced renal cell carcinoma (TA463)
Evidence-based recommendations on cabozantinib (Cabometyx) for previously treated advance renal cell carcinoma in adults.
This guideline covers assigning recall intervals between oral health reviews that are appropriate to the needs of individual patients. The guideline takes account of the effect of dental checks on: people’s wellbeing, general health and preventive habits; caries incidence and avoiding restorations; periodontal health and avoiding tooth loss; and avoiding pain and anxiety. It aims to improve or maintain patients’ quality of life and reduce morbidity associated with oral and dental disease.
Liposomal bupivacaine for treating postoperative pain [ID3799]
Topic prioritisation
This guideline covers the components of a good patient experience. It aims to make sure that all adults using NHS services have the best possible experience of care.
View recommendations for CG138Show all sections
In development Reference number: GID-TA11162 Expected publication date: 28 July 2027
Highly specialised technologies evaluation committee members
Biographies for each member of the highly specialised technologies evaluation committee.
Odevixibat for treating cholestasis and pruritus in Alagille Syndrome [ID6181]
In development Reference number: GID-TA11154 Expected publication date: TBC
This guideline covers assessment of people aged 16 and over with symptoms and signs of acute respiratory infection (bacterial or viral) at first remote or in-person contact with NHS services. It also covers the initial management of any infections. It aims to support healthcare practitioners in making sure that people’s treatment follows the best care pathway. It forms part of a suite of work on virtual wards being undertaken by NICE.
Study NICE and LSE's Executive MSc Healthcare Decision-Making
Study NICE and LSE's Executive MSc Healthcare Decision-Making
Maralixibat for treating progressive familial intrahepatic cholestasis [ID3818]
In development Reference number: GID-TA11410 Expected publication date: TBC
Awaiting development Reference number: GID-TA11343 Expected publication date: TBC
Depression in children and young people: identification and management (NG134)
This guideline covers identifying and managing depression in children and young people aged 5 to 18 years. Based on the stepped-care model, it aims to improve recognition and assessment and promote effective treatments for mild and moderate to severe depression.
Antimicrobial stewardship: changing risk-related behaviours in the general population (NG63)
This guideline covers making people aware of how to correctly use antimicrobial medicines (including antibiotics) and the dangers associated with their overuse and misuse. It also includes measures to prevent and control infection that can stop people needing antimicrobials or spreading infection to others. It aims to change people’s behaviour to reduce antimicrobial resistance and the spread of resistant microbes.
Ravulizumab for treating paroxysmal nocturnal haemoglobinuria (TA698)
Evidence-based recommendations on ravulizumab (Ultomiris) for treating paroxysmal nocturnal haemoglobinuria in adults.
Antisocial personality disorder: prevention and management (CG77)
This guideline covers principles for working with people with antisocial personality disorder, including dealing with crises (crisis resolution). It aims to help people with antisocial personality disorder manage feelings of anger, distress, anxiety and depression, and to reduce offending and antisocial behaviour.
This process guide explains how treatment option summaries for multiple guidelines were developed in an open, transparent, and timely way, with appropriate expert input
Find out more about the NICE technology appraisal advisory committee B members and their registered interests
This guideline covers diagnosing and managing abdominal aortic aneurysms. It aims to improve care by helping people who are at risk to get tested, specifying how often to monitor asymptomatic aneurysms, and identifying when aneurysm repair is needed and which procedure will work best.
This quality standard covers assessing, diagnosing and managing rheumatoid arthritis in over 16s. It describes high-quality care in priority areas for improvement.
This quality standard covers managing diabetes and its complications in women who are planning a pregnancy or are already pregnant. It includes care for women with pre-existing diabetes before and during pregnancy, and diagnosis and management of gestational diabetes. It describes high-quality care in priority areas for improvement.
View quality statements for QS109Show all sections
Sections for QS109
- Quality statements
- Quality statement 1: Preconception planning
- Quality statement 2: Joint diabetes and antenatal team care
- Quality statement 3: Continuous glucose monitoring
- Quality statement 4: Postnatal testing and referral
- Quality statement 5: Annual HbA1c tests
- Update information
- About this quality standard
Outside interests of the NICE board